Loading...
OTC Markets
Totals
Securities
12,312
Dollar Vol
$1.9B
Share Vol
3.6B
Trades
359,836

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

OTLC
Oncotelic Therapeutics, Inc.

Common Stock

0.058

0.0035

6.42%

0.0493 / 0.058 (25000 x 21301)

Real-Time Best Bid & Ask: 05:00pm 07/14/2025
Delayed (15 Min) Trade Data: 12:00am 07/14/2025

0.058

0.0449 - 0.058

11,118

Market Cap calculated only for this class of securities.

23,621,843

Real-Time Level 2 Quote
Trade Data
News
Filings and Disclosure
Company Description
Oncotelic Therapeutics, Inc. Company Logo
Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin).against certain oncology indications and viral infections. The program is being funded by our partner GMP through a JV that we are intend to take IPO. In addition, we are developing our VDA agents (Oxi4503/CA4P) various tumors, including three rare pediatric tumors (DIPG, Melanoma, and AML). 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas).
Videos
OTCQB Venture Market Logo
Joined OTCQB 06/2018
The Company Profile data was verified by the issuer within the previous 6 months.
This security is not a Penny Stock as defined in SEC Rule 240.3a51-1.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.